Hematology, Internal Medicine, Pediatrics, Pneumology
Conditions
Keywords
voriconazole, saliva, pharmacokinetics
Brief summary
The purpose of this study is to investigate the intra-saliva penetration of voriconazole in different subpopulations. The goal is to develop, optimize and validate an easy, non-invasive and painless procedure for Therapeutic Drud Monitoring of voriconazole that can be used in children, ambulatory patients and in patients in whom blood drawing is difficult.
Interventions
None listed
Sponsors
Universitaire Ziekenhuizen KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients from the adult hematology ward treated with voriconazole * pediatric patients treated with voriconazole, age 5-18 years * patients from the pneumology ward treated with voriconazole
Exclusion criteria
* Age under 5 years * Women who are pregnant or lactating * Mucositis stage 3 or 4 (WHO) * Patients which received the following drugs within 14 days before study entry: rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz and barbiturates. * Patients which received the following drugs within 24hours before study entry: quinidine, ergotamine, sirolimus, saquinavir, amprenavir, nelfinavir, ritonavir and sulphonylureas.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Voriconazole pharmacokinetics in saliva and plasma in different patient populations | One day at steady state of voriconazole plasma levels |
Countries
Belgium
Outcome results
None listed